Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
3.145
-0.065 (-2.02%)
At close: Dec 20, 2024, 4:00 PM
3.150
+0.005 (0.16%)
After-hours: Dec 20, 2024, 6:49 PM EST
Lantern Pharma Employees
Lantern Pharma had 21 employees as of December 31, 2023. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
n/a
Profits / Employee
-$909,140
Market Cap
33.92M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BioAtla | 65 |
Surrozen | 42 |
Envoy Medical | 34 |
Elevation Oncology | 29 |
Outlook Therapeutics | 24 |
NEXGEL | 19 |
BioVie | 14 |
Marker Therapeutics | 8 |
LTRN News
- 12 days ago - Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
- 18 days ago - Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) - Business Wire
- 25 days ago - Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality - Business Wire
- 4 weeks ago - Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients - Business Wire
- 6 weeks ago - Lantern Pharma Inc. (LTRN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates - Business Wire
- 6 weeks ago - Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board - Business Wire
- 7 weeks ago - Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET - Business Wire